Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

NCT00051584 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: SGN-15 (cBR96-Doxorubicin Immunoconjugate)
DRUG: Gemzar (Gemcitabine)

Sponsor

Seagen Inc.